Success Metrics

Clinical Success Rate
96.0%

Based on 48 completed trials

Completion Rate
96%(48/50)
Active Trials
6(9%)
Results Posted
33%(16 trials)
Terminated
2(3%)

Phase Distribution

Ph not_applicable
5
7%
Ph phase_1
1
1%
Ph phase_2
11
16%
Ph phase_3
16
24%
Ph phase_4
10
15%

Phase Distribution

1

Early Stage

11

Mid Stage

26

Late Stage

Phase Distribution43 total trials
Phase 1Safety & dosage
1(2.3%)
Phase 2Efficacy & side effects
11(25.6%)
Phase 3Large-scale testing
16(37.2%)
Phase 4Post-market surveillance
10(23.3%)
N/ANon-phased studies
5(11.6%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

94.1%

48 of 51 finished

Non-Completion Rate

5.9%

3 ended early

Currently Active

6

trials recruiting

Total Trials

67

all time

Status Distribution
Active(8)
Completed(48)
Terminated(3)
Other(8)

Detailed Status

Completed48
unknown8
Recruiting4
Active, not recruiting2
Terminated2
Not yet recruiting2

Development Timeline

Analytics

Development Status

Total Trials
67
Active
6
Success Rate
96.0%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (2.3%)
Phase 211 (25.6%)
Phase 316 (37.2%)
Phase 410 (23.3%)
N/A5 (11.6%)

Trials by Status

active_not_recruiting23%
completed4872%
recruiting46%
terminated23%
unknown812%
withdrawn11%
not_yet_recruiting23%

Recent Activity

Clinical Trials (67)

Showing 20 of 67 trialsScroll for more
NCT07753200Phase 4

Net Clinical Benefit of Edoxaban Versus Apixaban in Patients With Atrial Fibrillation and Coronary Artery Disease

Recruiting
NCT04618913

Anticoagulation in Patients With Venous Thromboembolism and Cancer

Completed
NCT05035277Phase 3

AntiCoagulation Versus AcetylSalicylic Acid After Transcatheter Aortic Valve Implantation

Completed
NCT05320627Phase 4

Population Pharmacokinetics of Edoxaban in Chinese Patients With Non-Valvular Atrial Fibrillation

Completed
NCT06650501Phase 4

Dabigatran vs. Oral Anti-Xa Inhibitors in S. Aureus Bacteremia

Recruiting
NCT03950076Phase 4

EdoxabaN foR IntraCranial Hemorrhage Survivors With Atrial Fibrillation (ENRICH-AF)

Active Not Recruiting
NCT03463317Phase 4

Left Atrial Appendage CLOSURE in Patients With Atrial Fibrillation Compared to Medical Therapy

Completed
NCT05804747

A Study to Evaluate Effectiveness and Safety of Edoxaban in Patients 80 Years of Age or Older With Nonvalvular Atrial Fibrillation

Completed
NCT05122455Phase 2

Effects of Edoxaban on Platelet Aggregation

Completed
NCT05732506

Safety Evaluation of Edoxaban in Elderly Patients With Frailty Criteria

Completed
NCT06449469Not Applicable

The Nordic Aortic Valve Intervention Trial 4 (NOTION-4)

Active Not Recruiting
NCT06900725Phase 2

Low Dose Edoxaban in Elderly Patients With AF and a History of Stroke

Not Yet Recruiting
NCT02943993

Edoxaban Treatment in Routine Clinical Practice in Patients With Venous Thromboembolism in Europe

Completed
NCT02798471Phase 3

Hokusai Study in Pediatric Patients With Confirmed Venous Thromboembolism (VTE)

Completed
NCT02618577Phase 3

Non-vitamin K Antagonist Oral Anticoagulants in Patients With Atrial High Rate Episodes

Terminated
NCT04747496

Real-world Study on Edoxaban Treatment for Patients With Non-valvular Atrial Fibrillation in China

Completed
NCT03840291Phase 4

Resolution of Thrombi in Left Atrial Appendage With Edoxaban

Completed
NCT06285942Not Applicable

EdOxaban in fRagIle Patients With Percutaneous Endoscopic GAstrostoMy and atrIal fIbrIllation

Recruiting
NCT04662515

NOACs in Oral and Maxillofacial Surgery: Impact on Post-operative Complications

Completed
NCT06149533Phase 3

Evaluate the Efficacy and Safety of Edoxaban on Prevention of Catheter-related Thrombosis (CRT) in Cancer Patients

Not Yet Recruiting

Drug Details

Intervention Type
DRUG
Total Trials
67